Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2016 - 2021)

Enanta Pharmaceuticals filings provide 8 years of Long-Term Deferred Tax readings, the most recent being $345000.0 for Q2 2021.

  • On a quarterly basis, Long-Term Deferred Tax fell 97.74% to $345000.0 in Q2 2021 year-over-year; TTM through Jun 2021 was $345000.0, a 97.74% decrease, with the full-year FY2020 number at $345000.0, down 96.96% from a year prior.
  • Long-Term Deferred Tax hit $345000.0 in Q2 2021 for Enanta Pharmaceuticals, roughly flat from $345000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $17.7 million in Q2 2017 to a low of $345000.0 in Q3 2020.
  • Median Long-Term Deferred Tax over the past 5 years was $9.2 million (2018), compared with a mean of $8.5 million.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 203.32% in 2017 and later tumbled 97.74% in 2021.
  • Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $7.6 million in 2017, then increased by 22.2% to $9.2 million in 2018, then rose by 15.22% to $10.7 million in 2019, then tumbled by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
  • The last three reported values for Long-Term Deferred Tax were $345000.0 (Q2 2021), $345000.0 (Q1 2021), and $345000.0 (Q4 2020) per Business Quant data.